Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial
- 1.4k Downloads
Olanzapine is effective in chemotherapy-induced nausea and vomiting (CINV). In patients receiving highly emetogenic chemotherapy (HEC), its efficacy was reported as rescue therapy for breakthrough emesis refractory to triplet therapy (palonosetron, aprepitant, and dexamethasone). However, its preventive effects with triplet therapy for CINV are unknown. This study aimed to investigate efficacy and safety of preventive use of olanzapine with triplet therapy for CINV of HEC.
This study is a prospective multicenter study conducted by Kansai Clinical Oncology Group. Forty chemo-naïve gynecological cancer patients receiving HEC with cisplatin (≥50 mg/m2) were enrolled. Oral olanzapine (5 mg) was administered with triplet therapy a day prior to cisplatin administration and on days 1–5. The primary endpoint was complete response (no vomiting and no rescue) rate for the overall phase (0–120 h post-chemotherapy). Secondary endpoints were complete response rate for acute phase (0–24 h post-chemotherapy) and delayed phase (24–120 h post-chemotherapy) and complete control (no vomiting, no rescue, and no significant nausea) rate and total control (no vomiting, no rescue, and no nausea) rate for each phase. These endpoints were evaluated during the first cycle of chemotherapy.
Complete response rates for acute, delayed, and overall phases were 97.5, 95.0, and 92.5 %, respectively. Complete control rates were 92.5, 87.5, and 82.5 %, respectively. Total control rates were 87.5, 67.5, and 67.5 %, respectively. There were no grade 3 or 4 adverse events.
Preventive use of olanzapine combined with triplet therapy gives better results than those from previously reported studies of triplet therapy.
KeywordsOlanzapine Chemotherapy-induced nausea and vomiting Cisplatin Highly-emetogenic chemotherapy Antiemetic therapy
We would like to express our gratitude to Tatsuya Morita, M.D., from Seirei Mikatahara General Hospital, Satoru Iwase, M.D., from Tokyo University, and members of the KCOG for advising us regarding the creation of this trial protocol. The authors thank Crimson Interactive Pvt. Ltd. (Ulatus)—www.ulatus.jp—for their assistance in manuscript translation and editing.
Conflict of interest
The authors declare that they have no competing interests.
- 2.MASCC/ESMO Antiemetic Guideline 2013. http://www.mascc.org/assets/documents/mascc_guidelines_english_2013.pdf Accessed 20 Mar. 2015.
- 4.National Comprehensive Cancer Network (2014) NCCN clinical practice guidelines in oncology: antiemesis, Version 1. http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf Accessed 20 Mar. 2015.
- 5.Japan Society of Clinical Oncology (2014) Guidelines for the proper use of antiemetics, version 1.2. Kanehara, Tokyo.Google Scholar
- 6.Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090–3098PubMedCrossRefGoogle Scholar
- 9.Hesketh PJ, Grunberg SM, Gralla RJ, et al. (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112–4119PubMedCrossRefGoogle Scholar
- 10.Takahashi T, Hoshi E, Takagi M, et al. (2011) Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci 11:2455–2461Google Scholar
- 13.Tamura K, Aiba K, Saeki T, et al. (2015) Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol 2015 Feb. 15.Google Scholar
- 14.Takeshima N, Matoda M, Abe M, et al. (2014) Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial. Support Care Cancer 22:2891–2898PubMedCrossRefGoogle Scholar
- 17.Liu J, Tan L, Zhang H, et al. (2014) QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist. Eur J Cancer Care 2014 Nov. 18.Google Scholar
- 20.Abe M, Kasamatsu Y, Kado N, et al. (2015) Efficacy of olanzapine combined therapy for patients receiving highly emetogenic chemotherapy resistant to standard antiemetic therapy. Biomed Res Int (in Press).Google Scholar
- 23.Morrow GR, Roscoe JA, Hickok JT, et al. (1998) Initial control of chemotherapy-induced nausea and vomiting in patient quality of life. Oncology (Williston Park) 12:32–37Google Scholar
- 27.Bymaster F, Perry KW, Nelson DL, et al. (1999) Olanzapine: a basic science update. Br J Psychiatry 37:36–40Google Scholar